去势抵抗性前列腺癌的发生机制及治疗进展

Mechanism and Treatment Progress of Castration-Resistant Prostate Cancer

前列腺癌是一种影响全球众多男性的复杂疾病,主要发生于人类发展指数较高的地区,且在老年男性中最常见。前列腺癌的发生机制主要包括雄激素受体超敏反应和肿瘤内替代雄激素的产生。但大部分前列腺癌患者经历足够长时间的雄激素消融治疗后仍可进展为去势抵抗性前列腺癌(CRPC)。目前针对CRPC的治疗方法主要包括派姆单抗、镭-223、放射性配体疗法和多聚ADP核糖聚合酶抑制剂等,而旨在改善前列腺癌检测方法和患者预后的研究也正在开展。因此,深入研究CRPC的发生机制,可以为疾病的治疗提供理论依据。

Prostate cancer is a complex disease affecting a large number of men worldwide,occurring mainly in areas with a high human development index,and is most common in elder men.The pathogenesis of prostate cancer mainly includes androgen receptor hypersensitivity and the production of replacement androgens within tumors.However,most patients with prostate cancer can still progress to castration-resistant prostate cancer(CRPC)after enough prolonged androgen ablation therapy.Current treatments for CRPC mainly include pembrolizumab,radium-223,radioligand therapy,and poly ADP-ribose polymerase inhibitors etc.,while studies on improving prostate cancer detection methods and patient prognosis are also underway.Therefore a further study of the mechanism of CRPC can provide a theoretical basis for the treatment of the disease.